CJC-1295: GHRH Analogue — Complete Scientific Analysis
Educational analysis of CJC-1295: differences between DAC and non-DAC versions, mechanism as GHRH analogue, clinical trial data from Teichman et al. (2006) and synergism with GHRP.
Educational Content Only
The information on this page is based on scientific publications and is for educational purposes only. It does not constitute medical prescription, diagnosis, therapeutic guidance, or recommendation for use. Any clinical intervention must be individualized by a qualified healthcare professional.
Mechanism of Action
CJC-1295 is a long-acting synthetic analogue of GHRH (Growth Hormone-Releasing Hormone). In its DAC (Drug Affinity Complex) form, it has a half-life of approximately 6–8 days due to covalent binding to serum albumin. Studies demonstrate it sustainably elevates basal GH and IGF-1 levels, unlike pulsatile secretagogues.
Data based on available scientific literature. Protocol individualization depends on qualified professional assessment.
Applications Described in the Literature
- ✓Sustained IGF-1 elevation documented in single and multiple dose studies
- ✓Body composition studies: lean mass increase and fat reduction
- ✓Research in post-exercise muscle recovery
- ✓Investigations in age-related GH deficiency
- ✓Combination models with GHSs for synergistic effect on the GH axis
Relevant Studies
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295
2006 · PMID: 16822960
Growth hormone-releasing hormone and its analogues: from bench to bedside
2014 · PMID: 24693169
Stimulation of GH secretion by GHS and GHRH: mechanisms and clinical applications
2009 · PMID: 19300232
Premium
✓ DesbloqueadoProtocols Described in the Literature
Protocols described in the literature distinguish CJC-1295 with DAC from CJC-1295 without DAC (Mod GRF 1-29). The non-DAC form has a short half-life (~30 minutes) similar to native GHRH, being used in more frequent administrations. The DAC form is described in weekly or twice-weekly dose studies, maintaining sustained IGF-1 elevation.
Dose Ranges Observed in Studies
- ◆CJC-1295 without DAC: ranges of 100–200 mcg observed in combination studies with GHSs
- ◆CJC-1295 with DAC: studies used 1–2 mg per weekly administration, with 2–3× baseline IGF-1 elevation
- ◆Duration in reference studies: 6–8 weeks for IGF-1 and body composition assessment
Effects Timeline (Literature)
Studies with CJC-1295 with DAC demonstrate detectable IGF-1 elevations after the first administration, peaking between 2–6 days. Maintenance of elevated IGF-1 for up to 14 days after single dose in some studies. Body composition effects observed in 6–8 week continuous use studies.
Documented Associations
- ↗Ipamorelin: most widely documented combination, complementary action on the GH axis
- ↗GHRP-2 and GHRP-6: documented in maximal stimulation studies, lower specificity
- ↗Tesamorelin: similar-acting alternative, FDA-approved for lipodystrophy
Monitoring Described in Studies
- ⊕Serum IGF-1: main response marker, with 2–3× elevations documented in studies
- ⊕Basal GH: may increase non-pulsatilely with DAC form
- ⊕Blood glucose: relevant monitoring in long-term use studies
- ⊕Peripheral edema: described in high-dose studies
Clinical Observations from Studies
- ℹThe non-DAC form is preferred in protocols aiming to mimic the physiological pulsatility of GH
- ℹThe DAC form continuously elevates GH and IGF-1, differing from the physiological pattern
- ℹSafety studies demonstrate absence of neutralizing antibodies in 8-week use
All information above is exclusively educational, based on scientific literature. It does not constitute medical prescription. Individualization of any protocol requires evaluation by a qualified healthcare professional.
Frequently Asked Questions
CJC-1295 with or without DAC — what is the difference?▼
CJC-1295 without DAC (Mod-GRF 1-29) has a half-life of ~30 minutes, producing physiological GH pulses. The DAC version binds to serum albumin, extending half-life to 6-8 days.
⚠️ Medical Disclaimer: The information on this page is based on scientific publications and is for educational purposes only. It does not constitute medical prescription, diagnosis, therapeutic guidance, or recommendation for use. Any clinical intervention must be individualized by a qualified healthcare professional.